Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Unlock leaner composition, improved metabolic health, and renewed confidence with Tesamorelin — the clinically studied peptide therapy designed to reduce visceral fat and support healthier aging.
What Tesamorelin
Targets abdominal (visceral) fat: Tesamorelin stimulates natural growth hormone–releasing pathways to specifically reduce harmful visceral adipose tissue, the fat linked to metabolic disease and cardiovascular risk.
Supports metabolic markers: Clinical evidence shows reductions in waist circumference and improvements in body composition that can positively influence metabolic health.
Preserves lean mass: By promoting endogenous growth hormone secretion rather than administering exogenous hormone, Tesamorelin helps protect muscle while targeting unwanted deep abdominal fat.
Fast, predictable results: Many patients see measurable reductions in visceral fat within months when used as part of a medically supervised program that includes nutrition and exercise.
Why choose Tesamorelin
Clinically validated: Tesamorelin has been evaluated in randomized controlled trials demonstrating meaningful reductions in visceral adiposity and waist circumference.
Well-defined mechanism: Works through growth hormone–releasing factor pathways to stimulate physiologic GH release, offering a targeted approach to visceral fat that differs from general weight-loss drugs.
Complementary to lifestyle medicine: Best used as part of a comprehensive plan — nutrition, exercise, and metabolic monitoring — to maximize durable outcomes.
Streamlined administration: Supplied as a subcutaneous injectable with established dosing protocols, enabling straightforward incorporation into your treatment offerings under medical oversight.
Available for research purposes
Unlock leaner composition, improved metabolic health, and renewed confidence with Tesamorelin — the clinically studied peptide therapy designed to reduce visceral fat and support healthier aging.
What Tesamorelin
Targets abdominal (visceral) fat: Tesamorelin stimulates natural growth hormone–releasing pathways to specifically reduce harmful visceral adipose tissue, the fat linked to metabolic disease and cardiovascular risk.
Supports metabolic markers: Clinical evidence shows reductions in waist circumference and improvements in body composition that can positively influence metabolic health.
Preserves lean mass: By promoting endogenous growth hormone secretion rather than administering exogenous hormone, Tesamorelin helps protect muscle while targeting unwanted deep abdominal fat.
Fast, predictable results: Many patients see measurable reductions in visceral fat within months when used as part of a medically supervised program that includes nutrition and exercise.
Why choose Tesamorelin
Clinically validated: Tesamorelin has been evaluated in randomized controlled trials demonstrating meaningful reductions in visceral adiposity and waist circumference.
Well-defined mechanism: Works through growth hormone–releasing factor pathways to stimulate physiologic GH release, offering a targeted approach to visceral fat that differs from general weight-loss drugs.
Complementary to lifestyle medicine: Best used as part of a comprehensive plan — nutrition, exercise, and metabolic monitoring — to maximize durable outcomes.
Streamlined administration: Supplied as a subcutaneous injectable with established dosing protocols, enabling straightforward incorporation into your treatment offerings under medical oversight.
Available for research purposes